Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Nature Medicine, Published online: 01 October 2026; doi:10.1038/s41591-026-04677-z An updated pooled analysis of 3-year and 5-year survival and other outcome data of 1,038 patients with melanoma treated with neoadjuvant immune checkpoint inhibitors (ICIs), BRAF and MEK inhibitors (BRAF/MEKis), or a combination of ICIs and targeted therapies shows that ICI as monotherapy or in ICI combinations are…

We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.

Read the original at nature.com →

More in Health & Medicine

More from Thursday 1 October →